Beigene divulges new EGFR mutant-targeting PROTACs for cancer

Nov. 25, 2022

Beigene Co. Ltd. has synthesized proteolysis targeting chimera (PROTAC) compounds comprising a cereblon (CRBN) E3 ubiquitin ligase-binding moiety covalently linked to an EGFR (mutant)-targeting moiety via linker.

BioWorld Science Cancer Patents

Today's news in brief

BioWorld

BioWorld briefs for May 14, 2026.

Illustration of a glowing circle to represent circRNA

ASGCT 2026: Circular RNA, the new beast in gene and cell therapy

BioWorld

Circular RNA (circRNA) is not a new concept, but it is a novel strategy in the field of gene and cell therapy. While mRNA vaccines have revolutionized medicine,...

Alzheimer’s, beyond the brain

BioWorld

Researchers at Daping Hospital in China have reported that liver-targeted delivery of the APOE3-Christchurch (APOE3Ch) variant, a rare protective form of...

News in brief

BioWorld Asia

BioWorld Asia briefs for May 12, 2026

Advancing the 'best of both' – BMS, Hengrui enter $15.2B deal

BioWorld

In a deal potentially worth up to $15.2 billion, Jiangsu Hengrui Pharmaceuticals Co. Ltd. is joining efforts with Bristol Myers Squibb Co. to advance 13 early...